Merck topped third-quarter analyst estimates on Thursday and raised its adjusted profit outlook. The company said sales of its immunotherapy Keytruda, including the newer injectable form Keytruda Qlex, were stronger than expected.
Merck now expects adjusted earnings of $2.77 to $2.82 per share, up from a previous range of $2.66 to $2.76. The new guidance includes a one-time charge of $400 million, or 12 cents per share, tied to a licensing agreement with the Chinese cancer drugmaker SciBrunch.
Keytruda brought in $8.60 billion in sales for the quarter, beating the $7.73 billion analysts expected, according to StreetAccount. Qlex accounted for $830 million of that, compared with analyst expectations of $649 million. That is the highest quarterly Qlex sales since the drug launched in 2025.
Merck posted third-quarter revenue of $18.09 billion, up 5% from a year earlier. Net income was $5.07 billion, or $2.04 per share, down from $5.79 billion, or $2.32 per share, a year earlier. Excluding acquisition and restructuring costs, the company reported earnings of $2.49 per share.
Other products also grew. Winrevair, which treats a rare, deadly lung condition, generated $694 million, up 93% from a year earlier and above the $645 million analysts expected. Gardasil, the HPV vaccine, drew about $2 billion in sales on higher U.S. demand, beating the $1.76 billion estimate. Merck's animal health business posted $1.68 billion in sales, slightly below estimates.
The report says Merck has been pursuing a series of deals to offset generic competition for Keytruda after key patents begin expiring in 2028. It also says Merck is positioning Qlex, a more convenient under-the-skin injection, as central to its growth strategy by moving patients from the original intravenous version.